NCT00370071View on ClinicalTrials.gov

Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Multiple Sclerosis
Interventions
DRUG

Interferon beta-1b (Betaseron, BAY86-5046)

Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)

Trial Locations (3)

100050

Beijing

100730

Beijing

200040

Shanghai

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00370071 - Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis | Biotech Hunter | Biotech Hunter